SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: IRWIN JAMES FRANKEL1/12/2007 8:17:15 AM
   of 10280
 
SEPR Sepracor: Operating leverage should result in earnings expansion in 2007 - AG Edwards (61.72 )

A.G. Edwards believes that SEPR is well-positioned to continue its strong growth in 2007, driven by all major product lines. Importantly, firm believes that the earnings leverage that SEPR possesses will become evident as revs accelerate to an estimated $1.5 bln in 2007, translating to fully diluted EPS of $2.76 for 2007. Although, firm does not recommend buying the stock on the anticipation of a SEPR acquisition, they recognize that there is a higher likelihood of a transaction occurring following the CMS decision to move to a National Coverage Decision for Xopenex, and they see few co's better positioned than SEPR as an attractive target.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News